Bronchial Asthma
Conditions
Keywords
Dyspnea, asthma control, peak expiratory flow rate
Brief summary
Bronchial asthma is a widespread chronic condition charactrized by inflammation and narrowing of airways, leading to repeateted episodes of breathlessness, wheezing and labored breathing.Breathing exercises help to manage hyperventilation often seen in asthmatic patients. To handle respiratory complications asthmatics are advised to practise nasal breathing techniques in conjunction with their prescribed medications.
Detailed description
Bronchial asthma is a very common chronic disease marked by inflammation and constriction of airways, resulting in recurrent episodes of breathlessness, wheezing and decrease work of breathing. Breathing exercises help to manage hyperventilation associated with asthma. In order to manage respiratory conditions asthmatic patients are encouraged for nasal breathing techniques along with pharmacological management. Hence the objective of the study is to compare the effects of alternative nostril breathing along with pharmacological management versus pharmacological management alone on dyspnea, control pause, asthma control and peak expiratory flow rate in patients with bronchial asthma.
Interventions
Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.
Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example: Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc. Week 01 and week 02: Patients will receive medication prescribed by pulmonologist. Week 03 and week 04: Patients will receive medication prescribed by pulmonologist.
Sponsors
Foundation University Islamabad
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a randomized controlled trial having two groups. One group will receive (interventional group) alternative nostril breathing along with pharmacological management and the other group (control group) will receive only pharmacological management.
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Adults: aged (18-45 years) * Gender: Both males and females * Grade1- Grade 4 on Modified MRC dyspnea scale * Asthma severity classes (intermediate, mild persistent and moderate persistent asthma) acc. to NAEPP national asthma education and prevention program guidlin
Exclusion criteria
* Patients having acute exacerbation of COPD or status asthmaticus * Patients diagnosed with acute infections * Patients unable to follow command/ instructions * Asthma patients with \>40 sec control pause duration * Patients who fall in red zone of asthma action plan (PEFR \< 50%)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dyspnea | 4 weeks | Evaluation will be done using Dyspnea-12 questionnaire for dyspnea |
| Control pause | 4 weeks | Stopwatch will be used to measure control pause. |
| Asthma control | 4 weeks | Asthma control test (ACT) will be used to evaluate asthma control and peak flow meter for peak expiratory flow rate. |
| Peak expiratory flow rate. | 4 Weeks | Peak flow meter will be used to measure peak expiratory flow rate |
Countries
Pakistan
Contacts
Primary ContactBazkha Tariq Aslam Khawaja, DPT
Outcome results
None listed